Join The Conversation!
https://bit.ly/SurfingNASHPodcast

A question from Ali Aminian leads the group to ponder whether cirrhosis can truly be regressed. The consensus is that many good things can happen (for example, fibrosis can be regressed) but that platelet levels never rebound.

From there, the panel considers the likely effect of the later-generation GLP-1s like semaglutide or tirzepatide, which report 10-15% overall weight loss, on MACE and MALO, as well as the in-development double and triple-agonists that report weight loss >20% in early studies.

S2-E61.3 - Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric S

Drug developers, investors, researchers, and corporate executives wrestle weekly to understand what is happening in commercial development of NASH medications. Hepatology researcher and Key Opinion Leader Stephen Harrison, M.D., C-suite veteran Peter Traber, M.D., and Forecasting and pricing guru Roger Green, M.B.A. discuss the issues affecting the evolving NASH market from their own unique perspectives on the Surfing the NASH Tsunami podcast.

S2-E61.3 - Can Weight Loss From GLP-1s or Double/Triple Agonists Emulate the Effects of Bariatric S

SurfingMASH